Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 306

The DOI matches its Crossref record; 238 of the 238 references it cites were found in a registry or an index.

Guidelines for the diagnosis and management of multiple myeloma 2011

Bird, Jennifer M., Owen, Roger G., D’Sa, Shirley, Snowden, John A., Pratt, Guy, Ashcroft, John, Yong, Kwee, Cook, Gordon, Feyler, Sylvia, Davies, Faith, Morgan, Gareth, Cavenagh, Jamie, Low, Eric, Behrens, Judith, on behalf of the Haemato‐oncology Task Force of the British Committee for Standards in Haematology (BCSH) and UK Myeloma Forum · 2011 · British Journal of Haematology

Abstract

In 2006 guidelines for the diagnosis and management of multiple myeloma were published (Smith et al, 2006). These current guidelines represent a major revision. The guideline has been split into two documents, focussing on the 'Diagnosis and management of multiple myeloma' and 'Supportive care in multiple myeloma 2011' (Snowden et al 2011). They are designed to be used together and to complement each other. The contents of 'Diagnosis and management of multiple myeloma' are listed below: Methodology, epidemiology and clinical presentation Diagnosis, prognostic factors and disease monitoring Imaging techniques Management of common medical emergencies in myeloma patients Myeloma bone disease Renal impairment Induction therapy including management of major toxicities and stem cell harvesting Management of refractory disease High dose therapy and autologous stem cell transplantation Allogeneic stem cell transplantation Maintenance therapy Management of relapsed myeloma including drugs in development Patient Information and Support The key areas that are covered comprehensively in the document entitled 'Guidelines for Supportive Care in Multiple Myeloma 2011' (Snowden et al 2011) are listed below: Anaemia Haemostasis and thrombosis issues Pain management Peripheral neuropathy Other symptom control – gastrointestinal, sedation/fatigue, mucositis Bisphosphonate-induced osteonecrosis of the jaw Complementary therapies End of life care The production of these guidelines involved the following steps: Establishment of working groups in the topic areas detailed above followed by review of key literature to 30th June 2010 including Cochrane database, Medline, internet searches and major conference reports. Development of key recommendations based on randomized, controlled trial evidence. In the absence of randomized data, recommendations were developed on the basis of literature review and a consensus of expert opinion. Involvement of patient advocacy through Myeloma UK. Review by UK Myeloma Forum (UKMF) Executive and British Committee for Standards in Haematology (BCSH) Committees. Review by a British Society for Haematology (BSH) sounding board. Levels of evidence and grades of recommendation are those of the US Agency for Healthcare Research and Quality (see Appendix I, Tables 1 and 2). In preparing these guidelines the authors have considered overall cost-effectiveness of recommended interventions as well as clinical efficacy data but formal health economic assessments have not been carried out. The annual incidence of myeloma in the UK is approximately 60–70 per million (http://info.cancerresearchuk.org/cancerstats/types/multiplemyeloma/incidence/index.htm). The overall prevalence is likely to be increasing given the recently published data demonstrating improved survival rates over the last decade (Kumar et al, 2008a; Brenner et al, 2009). The median age at presentation is approximately 70 years. Only 15% of patients are aged <60 years. Myeloma has a higher incidence in Afro-Caribbean ethnic groups than in Caucasians but there are few other distinctive epidemiological features. The majority of cases present de novo but it is now recognized that myeloma is preceded by an asymptomatic monoclonal gammopathy of undetermined significance (MGUS) phase in virtually all patients (Landgren et al, 2009). Presenting clinical features include symptoms of: Bone disease Impaired renal function Anaemia Hypercalcaemia Recurrent or persistent bacterial infection Hyperviscosity Other patients are diagnosed following the incidental detection of a raised erythrocyte sedimentation rate (ESR), plasma viscosity, serum protein or globulin. Patients with suspected myeloma require urgent specialist referral. Spinal cord compression, hypercalcaemia and renal failure are medical emergencies requiring immediate investigation and treatment. Investigation of a patient with suspected myeloma should include the screening tests indicated in Table I, followed by further tests to confirm the diagnosis. Electrophoresis of serum and concentrated urine should be performed, followed by immunofixation to confirm and type any M-protein present. Immunofixation and serum-free light chain (SFLC) assessment are indicated in patients where there is a strong suspicion of myeloma but in whom routine serum protein electrophoresis is negative (Pratt, 2008). Quantification of serum M-protein should be performed by densitometry of the monoclonal peak on electrophoresis; immunochemical measurement of total immunoglobulin (Ig) isotype level can also be used and is particularly useful for IgA and IgD M-proteins. Quantification of urinary total protein and light chain excretion can be performed directly on a 24 hour (h) urine collection or calculated on a random urine sample in relation to the urine creatinine. Quantification of SFLC levels and κ/λ ratio is an additional tool for the assessment of light chain production. The serum tests are particularly useful for diagno

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2141.2011.08573.x

Cites

238 of 238 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 238 references

Cited by

See all 306

Metadata

Authors
Bird, J. M., Owen, R. G., D’Sa, S., Snowden, J. A., Pratt, G., Ashcroft, J., Yong, K., Cook, G., Feyler, S., Davies, F., Morgan, G., Cavenagh, J., Low, E., Behrens, J., & on behalf of the Haemato‐oncology Task Force of the British Committee for Standards in Haematology (BCSH) and UK Myeloma Forum
Venue
British Journal of Haematology
Publisher
Wiley
Published
2011-05-14
Volume
154
Issue
1
Pages
32-75
ISSN
  • 0007-1048 (ISSN-L)
  • 1365-2141
OpenAlex
W1594485137
Cited by
306
References
238
FWCI
24.52
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Guidelines for the diagnosis and management of multiple myeloma 2011. https://app.cochat.ai/papers/10.1111/j.1365-2141.2011.08573.x
The paper
Bird, J. M., Owen, R. G., D’Sa, S., Snowden, J. A., Pratt, G., Ashcroft, J., Yong, K., Cook, G., Feyler, S., Davies, F., Morgan, G., Cavenagh, J., Low, E., Behrens, J., & on behalf of the Haemato‐oncology Task Force of the British Committee for Standards in Haematology (BCSH) and UK Myeloma Forum. (2011). Guidelines for the diagnosis and management of multiple myeloma 2011. British Journal of Haematology. https://doi.org/10.1111/j.1365-2141.2011.08573.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.